Industrie

• Azzeramento di tutti ×
• Scienze di vita ×

Showing 491–500 of 506 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  Autoimmune Diseases Treatment Market in China 2021

  The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Chimeric Antigen Receptor (CAR) T-Cell Therapy Market in China 2021

  In terms of revenue, the chimeric antigen receptor (CAR) T-cell therapy market in China is projected to grow at a compound annual growth rate (CAGR) of 17% over the analysis period of 2021 A 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the chimeric antigen receptor (CAR) T-cell therapy market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Myelodysplastic Syndromes (MDS) Drug Market in China 2021

  The myelodysplastic syndromes (MDS) drug market in China in terms of revenue is set to grow by US$ 548 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the myelodysplastic syndromes (MDS) drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Non-Small Cell Lung Cancer (NSCLC) Drug Market in China 2021

  The non-small cell lung cancer (NSCLC) drug market in China in terms of revenue is set to grow by US$ 13 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.1% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the non-small cell lung cancer (NSCLC) drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Hepatocellular Carcinoma (HCC) Drug Market in China 2021

  The hepatocellular carcinoma (HCC) drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 21.7% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the hepatocellular carcinoma (HCC) drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Diffuse Large B Cell Lymphomas (DLBCL) Drug Market in China 2021

  The diffuse large B cell lymphomas (DLBCL) drug market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 22.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the diffuse large B cell lymphomas (DLBCL) drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Multiple Myeloma Drug Market in China 2021

  The multiple myeloma drug market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 18.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the multiple myeloma drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Oncology Drug Market in China 2021

  The oncology drug market in China in terms of revenue is set to grow by US$ 42 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.8% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the oncology drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  Moderate and Severe Dry Eye Disease Market in China 2021

  The moderate and severe dry eye disease market in China in terms of revenue is set to grow by US$ 570 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 30.4% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the moderate and severe dry eye disease market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450
• 

  NMOSD (Neuromyelitis Optica Spectrum Disorder) Drug Market in China 2021

  In terms of revenue, the NMOSD (neuromyelitis optica spectrum disorder) drug market in China is projected to grow at a compound annual growth rate (CAGR) of 26.8% over the analysis period of 2021 A 2027, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the NMOSD (neuromyelitis optica spectrum disorder) drug market to help drive informed decision making for industry executives, decisori politici, academic, and analysts.

  Dollaro statunitense 450